Positive Phase 2 Data From Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN)' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting
5/1/2013 11:37:20 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to Follow
4/18/2013 11:32:08 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN)' HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment
2/27/2013 11:44:31 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) to Present at Cowen and Company Annual Healthcare Conference
2/26/2013 11:14:46 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) to Present at OneMedForum San Francisco 2013
1/3/2013 9:13:58 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Reports Third Quarter 2012 Financial Results
10/25/2012 9:22:41 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes
10/23/2012 8:54:05 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) to Report 3rd Quarter Financial Results on October 25, 2012; Conference Call to Follow
10/18/2012 9:05:51 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) to Present at 3rd Annual Cancer Immunotherapy Conference
9/28/2012 10:21:58 AM
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) to Present at the NewsMakers in the Biotech Industry Conference and the Rodman & Renshaw Global Investment Conference
9/4/2012 9:40:07 AM
More...
|
|